CONGRESS | POSTER | #ASH23 | Kenneth J C Lim @StVincentsMelb presents on the impact of 1Q21+ in daratumumab treated MM. median PFS with vs without 1q21+ 9.2-mo vs 22.1-mo. Median PFS gain1q21 vs amp1q21 5.7-mo vs 10.5mo. #mmsm #myeloma

1/ The "this shoulda been an oral" #MMsm poster of #Tandem25 - worth reviewing if you use cilta-cel! Rapid or sustained ALC ⬆️⬆️ appear to drive tox with BCMA CAR-T. CBCI now starting dex preemptively if ALC > 5.0 even if no tox yet - well-powered RCT hopefully coming soon!

2/ Independent proof of this principle from another of my top 10 #Tandem25 posters, this time by Yi Lin Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Mayo Myeloma et al: If peak ALC >3.0 after #MMsm CAR-T, 29% MNT risk if 3% if not. If Parkinsonism happens, use high-dose Cy quickly - possible Sx resolution.